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Enterolactone (EL) is an enterolignan found in human subjects. In this pilot study, the enantiomeric ratios of serum EL were
determined in serum from healthy adults during consumption of habitual diet, and after an 8-day supplementation with ﬂaxseed
(25g/day). (−)EL dominated in all serum samples collected during habitual diet consumption. However, the ratio of (−)EL and
(+)EL enantiomers diﬀered markedly between individuals. Flaxseed ingestion increased signiﬁcantly the proportion of (+)EL in
all subjects. Moreover, a small but signiﬁcant increase in serum (−)EL concentration was measured. After ﬂaxseed ingestion,
(−)EL concentrations correlated with those of (+)EL suggesting that the stereochemistry of the parent plant lignan in ﬂaxseed
is not a major determinant of EL formation in human subjects. Comparison of EL concentrations obtained with the validated
chromatographic methods (HPLC-MS/MS, HPLC-CEAD, and GC-MS) and the time-resolved ﬂuoroimmunoassay (TR-FIA)
revealed that the immunoassay method underestimates human serum EL concentrations after the ﬂaxseed ingestion.
1.Introduction
Enterolactone (EL) is an enterolignan produced by intestinal
microbiota from several dietary plant lignans [1]. In several
epidemiological studies, low serum and urine EL concentra-
tions have been associated with an increased risk for breast,
prostate, and colon cancers, and cardiovascular disease [2–6]
suggesting a possible role of EL as a protective agent against
the development of chronic diseases.
EL is a chiral compound, and the enantiomers occurring
as plant lignan metabolites are (8R, 8 R)-(−)EL and (8S,
8 S)-(+)EL (Figure 1) .O u rp r e v i o u ss t u d i e si nr a t sh a v e
demonstrated that the absolute conﬁguration at C8 and
C8  of the parent plant lignan is not changed during the
intestinal metabolism to EL [7]. Therefore, the ratio of (+)
and (−) enantiomers of formed EL is determined by the
stereochemistry of the plant lignan precursors. Whether the
stereochemistry determines metabolic conversion capability
of plant lignans to enterolignans is not yet known.
Since the ﬁrst published report on the identiﬁcation
and quantiﬁcation of EL in human plasma [8], several
chromatographic methods for measurement of EL in human
serum samples have been developed [9]. Later, a time-
resolved ﬂuoroimmunoassay (TR-FIA) methodology for EL
measurement was developed [10], and this method has
been used in majority of the large, population-based studies
investigating the relationship between human serum or
plasma EL concentration and the risk of a particular disease
[11–13]. The high sensitivity, wide working range, and easy
to perform technique of the immunoassay have enabled2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 1: Chemical structure of enterolactone enantiomers.
rapid analyses of EL in large sample sets [10]. However,
the suitability of the method has not yet been evaluated
for samples expected to contain high EL concentrations
(like after ﬂaxseed consumption) or diﬀerent ratio of EL
enantiomers.
In this pilot study, we measured for the ﬁrst time the
concentrations of EL enantiomers in serum from adult
volunteers consuming their habitual diet and after ﬂaxseed
ingestion and evaluated whether the serum EL enantiomer
proﬁle was associated with the serum enterolignan con-
centrations. Moreover, the serum EL concentration lev-
els obtained with TR-FIA and validated chromatographic
methods were compared (GC-MS, HPLC-MS/MS, HPLC-
coulometric electrode array detection (CEAD)) to evaluate
the suitability of the immunoassay method for the analysis
of serum samples after ﬂaxseed ingestion.
2.MaterialsandMethods
2.1. Serum Samples. The used study protocol was reviewed
and approved by the ethical committee of the Hospital
District of Southwest Finland and all participants gave their
informed consents. Blood samples were collected from ﬁve
female and ﬁve male Finnish healthy volunteers, aged 22–
58 years consuming their habitual diet (samples 1–5, and
6–10, resp.) and after eight days supplementation with 25
grams of crushed ﬂaxseed per day (samples 11–15, and 16–
20, resp.). The samples were collected 12 hours after the last
dose of ﬂaxseed. The serum was separated by centrifugation
a n ds t o r e da t−20◦C.
2.2. Analysis of Serum Enterolactone. The human serum
samples were analyzed for EL concentrations in three
laboratories (I-III) in Finland. The EL used for the standards
in laboratories I and II was purchased from VTT Technical
Research Centre of Finland (Espoo, Finland). In laboratory
III, the EL used for standards was synthesized in Prof.
Kristiina W¨ ah¨ al¨ a’s laboratory in the Department of Organic
Chemistry at the University of Helsinki, Finland.
In laboratory I, the enantiomers of EL in serum were
determined with an HPLC-MS/MS method as previously
described [7]. The serum ED and EL concentrations were
determined using an HPLC-MS/MS method as previously
described [14]. In laboratory II, the serum samples were
analyzed with HPLC-CEAD [15] with slight modiﬁcations.
Samples were puriﬁed prior to HPLC analysis with QAE-
Ac−-ion exchange gel as described earlier for urine analysis
[16]. Chromatographic separation was an isocratic 35-min
run with the same eluents as published earlier [15], but
the mobile phase consisted of 70% eluent B, and the
quantiﬁcation potential was 680mV. Quantiﬁcation was
carried out with the standard addition method using blank
plasma treated like a sample and containing added EL
from 6.8 to 170nM. Original estradiol glucuronide recovery
standardwasnolongerneededbecausethestandardaddition
method takes recovery corrections into account during the
quantiﬁcation.Sampleswhichexceededthecalibrationrange
were diluted with blank plasma prior to sample pretreatment
to work on calibration range. In laboratory III, the serum
samples were analyzed using GC-MS [8] but carrying out
the hydrolysis subsequently without separate extraction of
the sulfates and glucuronides, and with HPLC-CEAD [17],
and TR-FIA [10] with further modiﬁcations [18]. Each
sample was analyzed once with the previously validated
chromatographic methods [8, 14–17]. In TR-FIA method,
two parallels of each sample were analyzed [10, 18]. Due to
limited volume of some of the serum samples, they were not
available for all analyses.
2.3. Statistical Analyses. The statistical analyses were per-
formed with Statistica software for Windows (Stat Soft,
Tulsa, OK). The diﬀerences in serum (+) and (−)EL
concentrations were analyzed with one-way analysis of
variance followed by LSD post-hoc test. Correlation of
the measured serum lignans was determined by Pearson
correlation coeﬃcient. The acceptable level of signiﬁcance
was set at P ≤ .05 for all analyses.
3. Results
In all analyzed human serum samples, the proportions
of EL enantiomers varied interindividually. In all samples
collected prior to the ﬂaxseed ingestion, (−)EL dominated





1W 22.3 32.7 nq
2W 6.7 15.8 6.1
3W 19 57.4 2.6
4W 4.9 11.9 nq
5W 5.3 5.7 nq
6M 6.3 10.9 nq
7M 41.3 44.5 nq
8M 10.6 11.9 nq
9M 9.2 13.1 nq
10M 4.3 5.7 nq
11W 1332.9 101.9 649.5
12W 977.7 81.6 1022.1
13W 1645.1 205.4 372.3
14W 239.9 22.3 369.6
15W 226.6 37.2 645.4
16M 116.6 44 968.9
17M 1063.5 82.5 237.2
18M 580.2 40.3 77.7
19M 467.9 58.4 1143.9
20M 140.5 81.1 1828.8
#Samples 1–10 are collected from healthy Finnish women (W) and men (M) having their habitual diet and samples, 11–20 are from the same individuals after
8 days of ﬂaxseed supplementation (25 grams per day). Samples with ED levels below the limit of quantiﬁcation are marked nq (non quantiﬁable).
Table 2: Human serum EL concentrations (nM) before and after ﬂaxseed ingestion measured by chromatographic and TRFIA methods.
Laboratory I II III
Method HPLC-MS/MS HPLC-CEAD GC-MS HPLC-CEAD TR-FIA
Samples#
1W 55 33.9 NA 32.7 28.1
2 W 22.5 12.3 NA 14.9 12.1
3 W 76.4 40 NA 53.1 28.4
4 W 16.8 11.9 NA 13.9 11.2
5 W 11 6.7 NA 12.1 9
6 M 17.2 6.9 NA 12.6 5.5
7 M 85.8 52.4 NA 54 52.9
8 M 22.5 14.5 NA 15.1 14.3
9 M 22.3 9.2 NA 13.1 10.2
10 M 10 7.3 NA 29.3 8.2
11 W 1434.8 NA NA NA NA
12 W 1059.3 930.9 886.2 1016.7 359.6
13W 1850.5 NA NA NA NA
14W 262.2 225.7 260.3 235.7 105.2
15W 263.8 220.8 190.8 219.8 127.9
16M 160.6 110 144.4 128.3 54.4
17M 1146 NA NA NA NA
18M 620.5 NA NA NA NA
19M 526.3 438 376.2 421.8 201.2
20M 221.6 161.7 167.6 142.6 108.4
#Samples 1–10 are collected from healthy Finnish volunteers having their habitual diet and samples 11–20, are from the respective individuals after 8 days of
ﬂaxseed supplementation (25 grams per day). Samples not available for analysis due to a limited sample volume are marked as NA. Samples collected from
women are marked with W and those collected from men with M.4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
increased signiﬁcantly both serum enterodiol (ED) and EL
concentrations of all individuals (P<. 05). In half of
the volunteers (2 women and 3 men), ED was the major
serum enterolignan. Flaxseed ingestion increased the serum
(+)EL concentrations signiﬁcantly to 23–188-fold, resulting
into its dominance in all samples. Also, a smaller (2–13-
fold) increase in serum (−)EL concentration was observed
after ﬂaxseed consumption (P<. 05). In samples collected
after ﬂaxseed consumption, (−)EL concentration correlated
positively with serum (+)EL concentrations (R = 0.87, P<
.05). However, the ED concentration did not correlate with
the total EL or EL enantiomer concentrations.
The serum EL concentrations obtained with all the
methodscorrelatedwitheachother(R = 0.92–0.99,P<. 05).
In serum samples with relatively low EL concentrations (i.e.,
collected from subjects on their habitual diets), the average
variation of the results obtained with chromatographic and
TR-FIA methods was larger (CV% 35.2 and 42.0, resp.)
than in samples with high EL concentrations collected after
the ﬂaxseed ingestion (CV% 14.4 and 33.4, resp.). After
ﬂaxseed ingestion, the lowest concentrations were measured
with TR-FIA in all human serum samples (Table 2). Those
were signiﬁcantly (P<. 05) lower than the concentrations
obtained with chromatographic methods (Table 2). The
highest concentrations were measured with HPLC-MS-MS
(Table 2) but those were not statistically diﬀerent from the
concentrations measured with GC or HPLC-CEAD.
4. Discussion
In this pilot study, we demonstrate for the ﬁrst time
that the ratio of (+) and (−)EL in human serum varies
signiﬁcantly between individuals having their habitual diet.
However, in all serum samples collected during habitual
diet consumption, (−)EL predominated. This indicates that
the majority of the dietary precursor plant lignans have
the same conﬁguration at the asymmetric carbons of the
lactone ring as (−)EL. Flaxseed, however, contains mostly
(+)secoisolariciresinol in diglycosylated form [19]. We have
previously shown in rats that secoisolariciresinol diglycoside
isolated from ﬂaxseed is a precursor for (+)EL [7]. In this
study,wedemonstratefortheﬁrsttimethat(+)ELdominates
also in human serum after the ﬂaxseed ingestion.
As m a l li n c r e a s ei ns e r u m( −)EL concentration was
observed after the ﬂaxseed consumption. This is likely due
to (−)secoisolaricireresinol, a minor lignan in ﬂaxseed [19],
that is a parent compound for (−)EL formation in vivo
[7]. Moreover, ﬂaxseed contains (+)pinoresinol [19]w h i c h
is further converted to (−)secoisolariciresinol [20, 21]. After
ﬂaxseed ingestion, the serum (−)EL concentrations corre-
lated signiﬁcantly with the (+)EL concentrations, despite the
small individual diﬀerences in (−)EL serum concentrations.
This suggests that the stereochemical structure of the plant
lignan precursors in ﬂaxseed is not the major determinant
for the EL production capacity of the intestinal microbiota
in human subjects.
In serum samples with high EL concentrations (i.e.,
aftertheﬂaxseedingestion),themeasuredELconcentrations
were signiﬁcantly lower with the immunoassay than with
the chromatographic methods. The dominance of (+)EL
in samples collected after the ﬂaxseed consumption may
have resulted in underestimation of EL concentrations
measured with the immunoassay method, as the antibodies
are often stereoselective [22]. Preliminary results suggest that
at high concentrations the antibody reacts predominantly
with (−)EL. Thus, for samples expected to contain high
EL concentrations with variable enterolactone enantiomer
ratios, other analytical methods should be preferred.
5. Conclusions
Weshowherefortheﬁrsttimethattheratioofhumanserum
(+) and (−)EL enantiomers varies and can be signiﬁcantly
altered by dietary supplementation with ﬂaxseed. Moreover,
we showed that the immunoassay is not an optimal quanti-
tation method for samples with very high EL concentrations
or with signiﬁcantly altered ratio of EL enantiomers like
the ones collected after the ﬂaxseed ingestion. Therefore,
chromatographic quantitation methods should be preferred
in ﬂaxseed intervention studies.
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